[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hellp-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hellp-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,66,95,118,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100632198","phase-4-vitamin-d-supplementation-among-pregnant-women-in-uganda-for-the-prevention-of-hypertensive-disorders-in-pregnancy-and-other-adverse-maternal-and-foetal-outcomes-100632198",false,"NCT07510568","Vitamin D Supplementation Among Pregnant Women in Uganda for the Prevention of Hypertensive Disorders in Pregnancy, and Other Adverse Maternal and Foetal Outcomes","Vitamin D Supplementation Among Pregnant Women in Uganda and for the Prevention of Adverse Obstetric Outcomes: a Randomized Controlled Trial","MAMA","Inclusion Criteria:\n\nWomen of age ≥ 18 years, who attend ANC services at St. Mary's Hospital Lacor, satisfying the following criteria:\n\n* with a viable intrauterine pregnancy,\n* at gestational age at recruitment between 13 weeks 0 days and 27 weeks 6 days, and\n* who consented to participate in the study.\n\nExclusion Criteria:\n\n* women already on Vitamin D treatment prescribed by a physician.","FEMALE","18 Years",{"count":20,"type":21},1980,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this randomised controlled trial is to investigate if vitamin D supplementation among pregnant women in Uganda prevents adverse maternal and foetal outcomes, with special emphasis on preeclampsia.\n\nThe main question it aims to answer is if Vitamin D supplementation, administered as oral vitamin D₃ at a dose of 2,000 IU once daily, from the time of recruitment to the time of delivery, reduces the incidence of preeclampsia, eclampsia and HELLP syndrome in pregnant women attending ANC at St. Mary's Hospital, Lacor, such incidence being monitored up to six (6) weeks after delivery.\n\nResearchers will compare the effect of oral 2.000 IU vitamin D daily (intervention group) vs. oral placebo daily (control group) on the prevalence of adverse maternal and foetal outcomes.",[27,28,29],"Preeclampsia","Eclampsia","HELLP Syndrome","NOT_YET_RECRUITING","2026-04-01",{"date":33,"type":34},"2026-04-03","ACTUAL",{"date":36,"type":21},"2026-06-01",{"date":38,"type":21},"2027-12-31",{"name":40,"class":41},"St Mary's Hospital, Lacor","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100621989","study-of-prognostic-values-of-platelet-indices-and-inflammatory-markers-in-patients-with-hellp-syndrome-100621989","NCT07377786","Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.","Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome( Observational Controlled Study)","Inclusion Criteria:\n\n* Pregnant women aged 18 and 45 years. Gestational age ranged from 28 to 41 weeks. Pregnant women diagnosed with HELLP syndrome. Preeclampsia with Hellp syndrome. Pt with HELLP syndrome was delivered by ceserian section(SC)then admitted to Intensive care unit (ICU) only normal singleton pregnancies without fetal congenital or chromosomal anomalies\n\nExclusion Criteria:\n\n* Patients with infection and fever. Women with a history of diabetes, hypertension, systemic or endocrine disorder, chronic infection, chronic renal disease Liver diseases. Blood diseases. Drugs affecting platelet counts or functions. Any history of membrane rupture",true,"45 Years",{"count":52,"type":21},60,"2 Days","OBSERVATIONAL","This study aims to evaluate the prognostic values of platelet indices and inflammatory markers in patients with HELLP syndrome as:- :-Primary outcome To investigate prognostic values of platelet indices and. . inflammatory markers in HELLP syndrome patients as main indices including (NLR-PLR-MPV-PDW and RDW). .\n\n-Secondary outcome. Evaluation complications of HELLP syndrome including. .\n\n* Maternal complication:- eclampsia, disseminated intravascular coagulation (DIC), liver rupture, placental abruption, stroke, and pulmonary or kidney failure. .\n* Fetal complication:-intra uterine fetal death(iufd) ,neonate need for admission to NICU , congintal anomalies .assess APGAR score (which assess appearance(skin color)-pulse(heart rate)-Grimace(reflex irritability)- Activity(muscle tone)-Respiratory(breathing efforts) or umblical cord PH\\\u003C7. .",[29],"2026-01-22",{"date":59,"type":34},"2026-01-30",{"date":61,"type":21},"2026-02-01",{"date":63,"type":21},"2026-12",{"name":65,"class":41},"Sohag University",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":76,"studyType":54,"phases":4,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100604578","pilot-project-renal-and-cardiovascular-tertiary-prevention-in-preeclampsia-100604578","NCT07151339","Pilot Project Renal and Cardiovascular Tertiary Prevention in Preeclampsia","Pilotprojekt Renale Und kardiovaskuläre Tertiärprävention Nach Präeklampsie","EagleEye3P","Inclusion Criteria:\n\n* older than 18 yrs\n* diagnosed preeclampsia, HELLP syndrome or kidney disease durig pregnancy\n\nExclusion Criteria:\n\n* unable for informed consent",{"count":75,"type":21},100,"12 Months","Tertiary prevention program for women with preeclampsia, HELLP syndrome, kidney disease and pregnancy or associated conditions, including founding of a biobank. (Observational study since no interference with regular path of treatment suggested in national and international guidelines)",[27,29,28,79],"Kidney Disease",[81,82,83],"cardiovascular prevention","preeclampsia","pregnancy","RECRUITING","2025-08-28",{"date":87,"type":34},"2025-09-03",{"date":89,"type":34},"2024-11-01",{"date":91,"type":21},"2030-11",{"name":93,"class":41},"University Hospital Schleswig-Holstein",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":94},"100477747","placental-acute-atherosis-reflecting-subclinical-atherosclerosis-100477747","NCT05500989","PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis","PEARLS","Inclusion Criteria:\n\n* Women aged ≥ 18 years\n* Controls: Women with an uncomplicated pregnancy at the moment of inclusion (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies)\n* Cases: Women diagnosed with a preeclamptic pregnancy at the moment of inclusion\n\nExclusion Criteria:\n\n• Women who do not want to be informed about the results of the tests, or women who do not want their general practitioner and specialist(s) to be informed about the test results\n\n* Allergy or intolerance to glyceryl trinitrate, betablockers or iodinated contrast media.\n* Controls: Pre-existing chronic hypertension treated with antihypertensive medication or autoimmune disorder.",{"count":103,"type":21},226,"Pregnancy is considered a cardiovascular (CV) stress test, and complicated pregnancies are associated with an increased risk for cardiovascular disease (CVD) later in life. Moreover, it is known that often the pregnancy induced CV adaptation does not resolve completely after a short postpartum (PP) period and it is not clear whether these induced changes will resolve over a longer period of time (i.e. in the upcoming months\u002Fyears after delivery).\n\nUnderstanding the cardiac adaptation during pregnancy and the reversal process in the postpartum period, as well as the factors that influence this these processes, may provide us not only insight in this mechanism, but may help us in identifying factors that may be target points for modification.",[106,29,107,108],"Pre-Eclampsia","Intrauterine Growth Restriction","Pregnancy","2024-12-03",{"date":111,"type":34},"2024-12-05",{"date":113,"type":34},"2016-11",{"date":115,"type":21},"2028-12",{"name":117,"class":41},"Maastricht University Medical Center",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":131,"conditions":132,"keywords":140,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100550855","phase-3-preeclampsia-intervention-netherlands-100550855","NCT06452498","Preeclampsia Intervention Netherlands","Metformin for the Prolongation of Pregnancy in Preterm Preeclampsia","PI-NL","Inclusion Criteria\n\nAll of the following:\n\n* Aged 18 years or older\n* Singleton pregnancy\n* Gestational age between 23+0 and 31+6 weeks\n* A diagnosis of preterm preeclampsia, defined according to modified International Society for the Study of Hypertension in Pregnancy (ISSHP) classification, including only those who have proteinuria (≥300 mg of protein in a 24-hour urine specimen or a protein-creatinine-ratio \\>50 in a single urine sample)\n* Estimated fetal weight \\>400 grams\n* No clear indication (maternal or fetal) or intention, by both the treating multidisciplinary team and the patient after counseling, to immediately deliver (or directly after corticosteroid administration) or to terminate the pregnancy otherwise.\n* Ability to understand English or Dutch\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria\n\nAny of the following:\n\n* Current use of metformin or a clinical indication for the use of metformin\n* A decision for immediate delivery (including cases where corticosteroids are administered with planned delivery directly after completion of treatment) or termination of pregnancy (e.g., due to disease severity in the patient combined with a dismal prognosis for the fetus), as made by the treating multidisciplinary team and the parent(s)\n* Contraindication(s) for the use of metformin (e.g., severe renal insufficiency, acute metabolic acidosis, severe liver insufficiency)\n* Use of drugs that might interact with metformin\n* Suspicion of a major fetal anomaly and\u002For chromosomal abnormality\n* Unable or unwilling to (completely) understand or provide informed consent, due to language, culture, or other barriers","50 Years",{"count":128,"type":21},180,[130],"PHASE3","The goal of this study is to find out if pregnant individuals with preterm preeclampsia (PE) who are treated with metformin can stay pregnant for longer, and if this is safe(r) for the mother and child. Preterm PE affects about 1 in 100 pregnant individuals in the Netherlands. Signs of preterm PE can be high blood pressure and protein in the urine in the second half of pregnancy (but before 32-34 weeks of pregnancy). Other symptoms can develop, such as problems with blood clotting and how well the blood cells, liver, lungs, and brain work. The disease can lead to serious complications for both the mother and child. The only way to cure preterm PE is to make sure the child is born, and many times, children have to be delivered (very) early (before 37 weeks). Children born (very) early can suffer from infections, breathing difficulties, and problems in their development.\n\nMetformin is a medicine used to treat high blood sugar during and outside of pregnancy. In a previous study in South Africa, women with preterm PE that used metformin were able to safely remain pregnant for an extra week. Similarly, the main goal of the Preeclampsia Intervention NetherLands (PI-NL) study is to see if patients with preterm PE in the Netherlands that use metformin can remain pregnant for a longer time than patients taking a placebo. A placebo is a look-a-like capsule that contains no active ingredients. Researchers, the treating medical team, and participants will not know which participant gets which treatment. In addition, all participants will receive the standard care that all preterm PE patients get.",[133,106,134,135,136,137,138,29,139],"Pre-Eclampsia Onset Less Than 37 Weeks","Pre-Eclampsia; Complicating Pregnancy","Pre-Eclampsia as Antepartum Condition","Pre-eclampsia or Eclampsia With Pre-existing Hypertension","Pre-Eclampsia; Affecting Fetus","HELLP Syndrome Complicating Pregnancy","HELLP",[141,142,143,144,145,146,108,147,148,29,149,27,150],"Preterm Preeclampsia","Metformin","RCT","Placebo","Gestational Prolongation","Treatment","Multicenter","Preterm","Hypertensive disorders of pregnancy","Randomized controlled trial","2024-06-05",{"date":153,"type":34},"2024-06-11",{"date":155,"type":21},"2024-08",{"date":157,"type":21},"2028-07",{"name":159,"class":41},"Amsterdam UMC",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":49,"sex":167,"minAge":168,"maxAge":4,"enrollmentInfo":169,"targetDuration":171,"studyType":54,"phases":4,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":94},"100545129","the-preeclampsia-registry-100545129","NCT06377878","The Preeclampsia Registry","TPR","Inclusion Criteria:\n\n* Women who were medically diagnosed with preeclampsia or a related hypertensive disorder of pregnancy (HDP) such as eclampsia or HELLP syndrome.\n* Female or Male relatives of affected women\n* Women who have never had preeclampsia or hypertensive disorders of pregnancy, but who would like to serve as \"controls\" in research studies of preeclampsia.\n* An authorized representative may complete the questionnaire and provide consent for a woman who had preeclampsia, but has died or is disabled as a result.\n\nExclusion Criteria:\n\n* Those unable to provide consent\n* Prisoners\n* Individuals unable to speak English","ALL","13 Years",{"count":170,"type":21},20000,"20 Years","The purpose of The Preeclampsia Registry is to collect and store medical and other information from women who have been medically diagnosed with preeclampsia or a related hypertensive (high blood pressure) disorder of pregnancy such as eclampsia or HELLP syndrome, their family members, and women who have not had preeclampsia to serve as controls. Information from participants will be used for medical research to try to understand why preeclampsia occurs, how to predict it better, and to develop experimental clinical trials of new treatments. The Registry will consist of a web-based survey and mechanism for collecting and reviewing medical records. This data will be utilized for immediate investigator-driven cross-sectional research projects (after proposal review by the Registry's scientific advisory board and as directed by the PI). Participants may also choose to be contacted regarding possible participation in future studies, about providing a biospecimen, as well as investigator-driven clinical trials. The Registry is anticipated to exist long-term and to serve as a foundation of participants from which to draw for studies of preeclampsia, anticipated to evolve as our scientific understanding of preeclampsia evolves.",[27,28,29,174,175],"Toxemia","Hypertensive Disorder of Pregnancy",[27,28,139,29,174,175,177,178,108,179,180,181,182],"Registry","Pregnancy Complication","Maternal Death","Premature","High Blood Pressure","Hypertension","2024-04-17",{"date":185,"type":34},"2024-04-22",{"date":187,"type":34},"2013-09-01",{"date":189,"type":21},"2040-05",{"name":191,"class":41},"Preeclampsia Foundation"]